Vinay Mathew Thomas, MD, and colleagues sought to determine the current treatment patterns and rates of attrition in patients with advanced urothelial cancer (aUC). Their retrospective cohort study utilized patient data from approximately 280 oncology clinics throughout the United States. Eligible patients had received treatment solely for metastatic or local aUC between January 2011 and January 2023. ...
Urothelial Carcinoma
Advertisement
Latest News
Continuing his discussion at the AUA 2024 Annual Meeting, Dr. Narayan highlights the latest news on nadofaragene firadenovec.
Dr. Narayan breaks down the 5-year follow-up data on nadofaragene firadenovec for patients with BCG-unresponsive NMIBC.
Drs. Ambinder and Sonpavde provide an update for CheckMate 901, characterizing treatment benefit in responders.
Drs. Murray and Broenimann highlight and evaluation of urinary genomic profiling for detection and molecular staging of UTUC.
Drs. Murray and Lotan review the development and validation of AI biomarkers to predict outcomes in BCG-treated NMIBC.
Drs. Murray and Lotan highlight a recent multicenter study featuring longitudinal follow-up of UGN-101 for UTUC.
Advertisement
Urothelial Carcinoma Knowledge Hubs
Curated clinical content based on urothelial cancer types, therapies, and technologies
Conference Coverage
Dr. Li highlights the significance of adverse pathologic features at radical prostatectomy for AS-eligible patients.
Continuing his discussion at the AUA 2024 Annual Meeting, Dr. Narayan highlights the latest news on nadofaragene firadenovec.
Dr. Narayan breaks down the 5-year follow-up data on nadofaragene firadenovec for patients with BCG-unresponsive NMIBC.
Development of a novel risk score for early intensification approaches to RT or salvage RT for pN1 receiving RP.
Drs. Joyce and Psutka consider patient counseling for adjuvant RCC therapy, and biomarkers and imaging before treatment.
Drs. Ambinder and Sonpavde provide an update for CheckMate 901, characterizing treatment benefit in responders.
Advertisement
Advertisement
Latest News
In patients with RCC, around 20% demonstrate non-clear cell histology, including various histology types.
Dr. Li highlights the significance of adverse pathologic features at radical prostatectomy for AS-eligible patients.
Previous research has shown that the effects of androgen and PSMA receptors can complement each other if used concurrently.
